Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

NCT00660972 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Raltegravir
DRUG: Emtricitabine/tenofovir disoproxil fumarate

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]